Opthea (OPT) Competitors $3.41 +0.23 (+7.23%) As of 08/14/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OPT vs. BLTE, IBRX, IRON, AGIO, TWST, CGON, HRMY, DNLI, MESO, and OCULShould you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Belite Bio (BLTE), ImmunityBio (IBRX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), CG Oncology (CGON), Harmony Biosciences (HRMY), Denali Therapeutics (DNLI), Mesoblast (MESO), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Opthea vs. Its Competitors Belite Bio ImmunityBio Disc Medicine Agios Pharmaceuticals Twist Bioscience CG Oncology Harmony Biosciences Denali Therapeutics Mesoblast Ocular Therapeutix Opthea (NASDAQ:OPT) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends. Is OPT or BLTE more profitable? Opthea's return on equity of 0.00% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Belite Bio N/A -34.90%-33.56% Do insiders & institutionals believe in OPT or BLTE? 56.0% of Opthea shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 3.2% of Opthea shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, OPT or BLTE? Belite Bio has lower revenue, but higher earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$120K4,373.61-$220.24MN/AN/ABelite BioN/AN/A-$36.14M-$1.55-42.99 Which has more risk and volatility, OPT or BLTE? Opthea has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.49, indicating that its stock price is 249% less volatile than the S&P 500. Do analysts recommend OPT or BLTE? Opthea currently has a consensus price target of $1.33, indicating a potential downside of 60.90%. Belite Bio has a consensus price target of $96.67, indicating a potential upside of 45.08%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts clearly believe Belite Bio is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor OPT or BLTE? In the previous week, Belite Bio had 18 more articles in the media than Opthea. MarketBeat recorded 20 mentions for Belite Bio and 2 mentions for Opthea. Opthea's average media sentiment score of 1.66 beat Belite Bio's score of -0.14 indicating that Opthea is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Opthea 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Belite Bio 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryOpthea beats Belite Bio on 7 of the 13 factors compared between the two stocks. Get Opthea News Delivered to You Automatically Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OPT vs. The Competition Export to ExcelMetricOptheaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$524.84M$3.10B$5.67B$9.82BDividend YieldN/A2.23%3.79%4.08%P/E RatioN/A20.3830.5825.12Price / Sales4,373.61368.96464.24116.42Price / CashN/A42.3037.4059.05Price / Book-6.098.659.096.18Net Income-$220.24M-$54.65M$3.25B$264.89M7 Day PerformanceN/A6.58%7.42%4.22%1 Month PerformanceN/A7.54%5.50%2.02%1 Year Performance32.68%13.73%30.67%24.22% Opthea Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OPTOpthea0.4082 of 5 stars$3.41+7.2%$1.33-60.9%+41.5%$524.84M$120K0.008News CoverageGap UpHigh Trading VolumeBLTEBelite Bio2.5524 of 5 stars$69.79+6.2%$96.67+38.5%+33.5%$2.09BN/A-51.3210News CoverageEarnings ReportAnalyst RevisionIBRXImmunityBio2.245 of 5 stars$2.41+1.7%$12.25+408.3%-35.9%$2.09B$14.74M-4.16590News CoverageAnalyst ForecastOptions VolumeIRONDisc Medicine3.3143 of 5 stars$59.79+1.4%$95.73+60.1%+23.9%$2.04BN/A-15.2530Insider TradeAGIOAgios Pharmaceuticals4.377 of 5 stars$36.16+3.3%$56.33+55.8%-17.6%$2.03B$36.50M3.29390Insider TradeHigh Trading VolumeTWSTTwist Bioscience3.9459 of 5 stars$30.21-10.3%$50.40+66.8%-37.5%$2.02B$312.97M-9.30990Positive NewsHigh Trading VolumeCGONCG Oncology1.3342 of 5 stars$26.09-0.8%$55.30+112.0%-25.3%$2.01B$1.14M-17.2861Earnings ReportAnalyst RevisionHRMYHarmony Biosciences4.5038 of 5 stars$35.54+3.3%$51.00+43.5%+4.6%$1.98B$714.73M13.56200DNLIDenali Therapeutics4.1655 of 5 stars$14.44+7.4%$33.85+134.4%-37.9%$1.95B$330.53M-5.41430Trending NewsEarnings ReportAnalyst RevisionMESOMesoblast2.4236 of 5 stars$15.43+1.7%$18.00+16.7%+153.9%$1.94B$5.90M0.0080OCULOcular Therapeutix4.0768 of 5 stars$12.35+3.6%$17.33+40.4%+50.8%$1.90B$63.72M-10.74230 Related Companies and Tools Related Companies BLTE Alternatives IBRX Alternatives IRON Alternatives AGIO Alternatives TWST Alternatives CGON Alternatives HRMY Alternatives DNLI Alternatives MESO Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OPT) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opthea Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Opthea With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access